Targeting flavin-containing enzymes eliminates cancer stem cells (CSCs), by inhibiting mitochondrial respiration: vitamin B2 (riboflavin) in cancer therapy.
Name:
MzqhgFvdDySCoyuLu.pdf
Size:
4.682Mb
Format:
PDF
Description:
Full text, Open Access article
Authors
Ozsvari, BelaBonuccelli, Gloria
Sanchez-Alvarez, Rosa
Foster, R
Sotgia, Federica
Lisanti, Michael P
Affiliation
Translational Medicine, School of Environment and Life Sciences, Biomedical Research Centre (BRC), University of Salford, Greater ManchesterIssue Date
2017-12-16
Metadata
Show full item recordAbstract
Here, we performed high-throughput drug-screening to identify new non-toxic mitochondrial inhibitors. This screening platform was specifically designed to detect compounds that selectively deplete cellular ATP levels, but have little or no toxic side effects on cell viability. Using this approach, we identified DPI (Diphenyleneiodonium chloride) as a new potential therapeutic agent. Mechanistically, DPI potently blocks mitochondrial respiration by inhibiting flavin-containing enzymes (FMN and FAD-dependent), which form part of Complex I and II. Interestingly, DPI induced a chemo-quiescence phenotype that potently inhibited the propagation of CSCs, with an IC-50 of 3.2 nano-molar. Virtually identical results were obtained using CSC markers, such as CD44 and CD24. We further validated the effects of DPI on cellular metabolism. At 10 nM, DPI inhibited oxidative mitochondrial metabolism (OXPHOS), reducing mitochondrial driven ATP production by >90%. This resulted in a purely glycolytic phenotype, with elevated L-lactate production. We show that this metabolic inflexibility could be rapidly-induced, after only 1 hour of DPI treatment. Remarkably, the mitochondrial inhibitory effects of DPI were reversible, and DPI did not induce ROS production. Cells maintained in DPI for 1 month showed little or no mitochondrial activity, but remained viable. Thus, it appears that DPI behaves as a new type of mitochondrial inhibitor, which maintains cells in a state of metabolic-quiescence or "suspended animation".In conclusion, DPI treatment can be used to acutely confer a mitochondrial-deficient phenotype, which we show effectively depletes CSCs from the heterogeneous cancer cell population. These findings have significant therapeutic implications for potently targeting CSCs, while minimizing toxic side effects. We also discuss the possible implications of DPI for the aging process. Interestingly, previous studies in C. elegans have shown that DPI prevents the accumulation of lipofuscin (an aging-associated hallmark), during the response to oxidative stress. Our current results are consistent with data showing that flavins (FAD, FMN and/or Riboflavin) are auto-fluorescent markers of i) increased mitochondrial "power" (OXPHOS) and ii) elevated CSC activity.Finally, we believe that DPI is one of the most potent and highly selective CSC inhibitors discovered to date. Therefore, our current findings suggest a new impetus to create novel analogues of i) DPI (Diphenyleneiodonium chloride) and ii) DPI-related compounds (Diphenyliodonium chloride), using medicinal chemistry, to optimize this very promising and potent anti-CSC activity. We propose to call these new molecules "Mitoflavoscins".For example, DPI is ~30 times more potent than Palbociclib (IC-50 = 100 nM), which is an FDA-approved CDK4/6 inhibitor, that broadly targets proliferation in any cell type, including CSCs.Citation
Targeting flavin-containing enzymes eliminates cancer stem cells (CSCs), by inhibiting mitochondrial respiration: vitamin B2 (riboflavin) in cancer therapy. 2017, 9(12): 2610-2628 Aging (Albany NY)Journal
AgingDOI
10.18632/aging.101351PubMed ID
29253841Type
ArticleLanguage
enISSN
1945-4589ae974a485f413a2113503eed53cd6c53
10.18632/aging.101351
Scopus Count
Collections
Related articles
- Regulation of respiratory complex I assembly by FMN cofactor targeting.
- Authors: Curtabbi A, Guarás A, Cabrera-Alarcón JL, Rivero M, Calvo E, Rosa-Moreno M, Vázquez J, Medina M, Enríquez JA
- Issue date: 2024 Feb
- Targeting cancer stem cell OXPHOS with tailored ruthenium complexes as a new anti-cancer strategy.
- Authors: Alcalá S, Villarino L, Ruiz-Cañas L, Couceiro JR, Martínez-Calvo M, Palencia-Campos A, Navarro D, Cabezas-Sainz P, Rodriguez-Arabaolaza I, Cordero-Barreal A, Trilla-Fuertes L, Rubiolo JA, Batres-Ramos S, Vallespinos M, González-Páramos C, Rodríguez J, Gámez-Pozo A, Vara JÁF, Fernández SF, Berlinches AB, Moreno-Mata N, Redondo AMT, Carrato A, Hermann PC, Sánchez L, Torrente S, Fernández-Moreno MÁ, Mascareñas JL, Sainz B Jr
- Issue date: 2024 Jan 27
- OXPHOS-targeting drugs in oncology: new perspectives.
- Authors: Kalyanaraman B, Cheng G, Hardy M, You M
- Issue date: 2023 Jul-Dec
- PGC1-α-driven mitochondrial biogenesis contributes to a cancer stem cell phenotype in melanoma.
- Authors: Fontana F, Macchi C, Anselmi M, Rizzuto AS, Ruscica M, Limonta P
- Issue date: 2024 Jan
- New insights into the nutritional genomics of adult-onset riboflavin-responsive diseases.
- Authors: Murgia C, Dehlia A, Guthridge MA
- Issue date: 2023 Oct 16